Polymedco LLC

Polymedco LLC, doing business as Polymedco Cancer Diagnostic Products, supplies automated fecal immunochemical test (FIT) analyzers, diagnostic reagents, testing kits with mailers, and cost-per-test laboratory services to the Department of Veterans Affairs as a prime contractor across 26 federal agencies, competing entirely through full and open procurement without set-asides. The company is a small disadvantaged business and for-profit organization headquartered in Cortlandt Manor, New York.

Polymedco's federal footprint concentrates almost entirely on colorectal cancer screening technologies for the Veterans Health Administration. The company's capability portfolio centers on automated immunochemical fecal occult blood (IFOBT) analyzers, fecal immunochemical test (FIT) kits with mailers, diagnostic reagents, and laboratory testing services performed on a cost-per-test basis. Recent representative work includes a $801,195 delivery order from Veterans Integrated Service Network 7 for FIT kits under the GSA Critical Analyzers, Laboratory Federal Supply Schedule (FSS-66-III), a $418,189.40 BPA call from VISN 22 for IFOBT cost-per-test solutions awarded June 5, 2025, and a $1.95 million parent Blanket Purchase Agreement with VISN 6 for fecal occult blood testing supplies and services established December 3, 2025 through December 2, 2029.

Customer concentration sits almost exclusively with the Department of Veterans Affairs Veterans Health Administration across distributed regional networks. The top five funding customers by potential value account for 85 percent of Polymedco's combined potential value: VISN 12 dominates with 67 awards worth $195.1 million in combined potential value; VISN 7 follows with 24 awards and $26.3 million; VISN 22 contributes 35 awards and $16.4 million; VISN 15 provides 18 awards and $10.6 million; and VISN 16 offers 78 awards and $9.5 million. By award count, VISN 10 places highest with 116 awards, though its $6.9 million potential value trails VISN 16's 78 awards valued at $9.5 million, revealing that VISN 12's concentration is driven by large individual contract values rather than volume.

Polymedco holds parent indefinite delivery vehicles (BPAs) on the GSA Critical Analyzers, Laboratory Federal Supply Schedule (FSS-66-III) with at least fifteen separate VISNs — Networks 1, 2, 4, 5, 6, 8, 9, 10, 12, 15, 16, 17, 19, 20, 21, 22, and 23 — plus the Indian Health Service. The Critical Analyzers vehicle anchors the portfolio, with 979 task orders carrying $140 million combined potential value. Individual parent BPA ceiling values range from $185,000 to $1.95 million, with performance periods extending through December 2029 and September 2031. This vehicle structure enables individual medical facilities within each VISN to issue Blanket Purchase Agreement calls on an as-needed basis for Polymedco's cancer diagnostic products without repeated competitive procurement.

Activity has grown from 67 awards in 2022 to 111 in 2024, with 109 awards in 2025 and 41 awards through mid-September 2026 in the source snapshot. Forty-eight awards (combined potential value $3.8 million) face ultimate completion in the next twenty-four months and therefore present recompete opportunity. Polymedco does not appear in the source as a subcontractor and operates exclusively as a prime contractor; 1,435 recent awards carry 100 percent prime designation and zero sub-award exposure.

The source identifies the company's subsidiary as Polymedco Cancer Diagnostic Products LLC, also registered as a small disadvantaged business. Polymedco competes entirely under full and open federal procurement — no set-aside awards appear in the recent portfolio. NAICS concentration sits heavily on Analytical Laboratory Instrument Manufacturing (712 awards) and In-Vitro Diagnostic Substance Manufacturing (106 awards). PSC coding clusters around Laboratory Equipment and Supplies (539 awards) and In Vitro Diagnostic Substances, Reagents, Test Kits and Sets (281 awards). The company's federal contracting footprint reflects deep specialization in colorectal cancer screening for the VA healthcare system, with standardized products and pricing mechanisms that enable efficient procurement across the distributed Veterans Health Administration network through established parent vehicle agreements extending through 2031.